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Abstract
Background: Tuberculous meningitis in adults is well characterized in Vietnam, but there are no data on the
disease in children. We present a prospective descriptive study of Vietnamese children with TBM to define the
presentation, course and characteristics associated with poor outcome.
Methods: A prospective descriptive study of 100 consecutively admitted children with TBM at Pham Ngoc Thach
Hospital, Ho Chi Minh City. Cox and logistic regression were used to identify factors associated with risk of death
and a combined endpoint of death or disability at treatment completion.
Results: The study enrolled from October 2009 to March 2011. Median age was 32.5 months; sex distribution was
equal. Median duration of symptoms was 18.5 days and time from admission to treatment initiation was 11 days.
Fifteen of 100 children died, 4 were lost to follow-up, and 27/81 (33 %) of survivors had intermediate or severe
disability upon treatment completion. Microbiological confirmation of disease was made in 6 %. Baseline
characteristics associated with death included convulsions (HR 3.46, 95CI 1.19–10.13, p = 0.02), decreased
consciousness (HR 22.9, 95CI 3.01–174.3, p < 0.001), focal neurological deficits (HR 15.7, 95CI 1.67–2075, p = 0.01),
Blantyre Coma Score (HR 3.75, 95CI 0.99–14.2, p < 0.001) and CSF protein, lactate and glucose levels. Neck stiffness,
MRC grade (children aged >5 years) and hydrocephalus were also associated with the combined endpoint of death
or disability.
Conclusions: Tuberculous meningitis in Vietnamese children has significant mortality and morbidity. There is
significant delay in diagnosis; interventions that increase the speed of diagnosis and treatment initiation are likely to
improve outcomes.
Keywords: Tuberculous meningitis, Children, Vietnam, Mycobacterium, Survival
* Correspondence: jday@oucru.org
1Oxford University Clinical Research Unit, Wellcome Trust Major Overseas
Programme, 764 Vo Van Kiet, Quan 5, Ho Chi Minh City, Vietnam
4Centre for Tropical Medicine and Global Health, Nuffield Department of
Medicine Research Building, University of Oxford, Old Road campus,
Roosevelt Drive, Oxford, UK
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Bang et al. BMC Infectious Diseases  (2016) 16:573 
DOI 10.1186/s12879-016-1923-2
Background
Tuberculosis (TB) is an important cause of childhood
morbidity - recent estimates of the number of children
developing TB each year range from 500 000 to 1 mil-
lion, significantly higher than previously estimated by
the WHO [1, 2]. There may be 50 million children la-
tently infected [3]. 5 % of disease occurs in HIV co-
infected children, although this is higher in sub-Saharan
Africa [3]. Despite this high burden, in TB as in many
other diseases, children are a neglected group - the vast
majority of data used to guide management are derived
from adult patients.
Tuberculous meningitis (TBM) is the most severe
form of tuberculosis, with high rates of disability and
death [4]. Children are more likely than adults to de-
velop disseminated TB and TB meningitis following in-
fection [5]. This risk is greatest for infants and children
under 2 years of age, probably due to the immaturity of
the immune system [6]. The challenges of TBM diagno-
sis and management are exacerbated in children. Initial
symptoms in infants are non-specific, it is difficult to ob-
tain diagnostic samples and more invasive sampling
methods are needed, and the diagnostics samples ob-
tained generally proffer extremely low yields of myco-
bacteria [7, 8]. Death from TBM is strongly associated
with delays in diagnosis and treatment both in children
and adults [9–12]. It is striking that there has never been
a randomized controlled trial of anti-tuberculosis drugs
in children with TBM [13].
Vietnam is classified as having a high burden of TB, with
a prevalence in the order of 145 per 100 000 of the popula-
tion as a whole [14]. Tuberculous meningitis in adults is
well characterized in Vietnam, and these data have been
key in developing treatment guidelines, but there are no
data on the disease in children [11, 15–17]. In accordance
with historic WHO policy, the Vietnamese National TB
Programme has focused on the systematic notification of
smear positive cases of TB. However, the majority of
pediatric TB cases are smear negative, and subsequently
limited data are available on pediatric TB in Vietnam. In
line with WHO policy revisions, Vietnam has recently im-
plemented disaggregated data collection for pediatric TB.
Improving outcomes in children is dependent upon a better
understanding of the epidemiology of childhood TB, and
early diagnosis and instigation of effective treatment.
Methods
Study aim
This study aimed to describe the current practice in the
management of Vietnamese children with TBM, the pre-
senting clinical features and predictors of poor outcome
(death and neurological disability), in order to define the
challenges in management and prioritise research.
Study design
A prospective descriptive study of 100 consecutive cases
of TBM in children (aged ≤15 years).
Setting and participants
The study was conducted at Pham Ngoc Thach Hospital
(PNT), Ho Chi Minh City (HCMC). PNT is the tertiary
referral centre for tuberculosis in the south of Vietnam,
serving 40 million people. All children diagnosed or sus-
pected of having TBM in HCMC and the surrounding
provinces are referred here. Approximately 500 inpatient
cases of pediatric TB are treated each year; around 20 %
have meningitis.
Entry criteria
All patients aged ≤15 years presenting to Pham Ngoc
Thach Hospital with a clinical syndrome consistent with
TBM (meaning one or more of: fever, headache, neck
stiffness, vomiting, confusion, coma, convulsions, cranial
nerve palsies, hemiplegia or paraplegia) and considered
to have tuberculous meningitis by their attending phys-
ician (i.e. meriting anti-TB therapy) were eligible to enter
the study. TBM was classified as “definite”, “probable” or
“possible”, as follows:
Definite TBM: acid-fast bacilli (AFB) seen or cultured
from cerebrospinal fluid (CSF).
Probable TBM: Clinical syndrome consistent with
TBM, and one or more of the following criteria:
suspected active pulmonary tuberculosis on chest
radiography, AFB found in any specimen other than
the CSF, brain imaging consistent with TBM, or clinical
evidence of other extrapulmonary tuberculosis.
Possible TBM: Clinical syndrome consistent with TBM
and at least 4 of the following: past medical history of
tuberculosis, predominance of lymphocytes in the CSF,
illness of ≥6 days in duration, CSF: blood glucose ratio
<0.5, altered consciousness, yellow CSF, and focal
neurological signs.
Patient assessment
All patients had clinical assessments by the dedicated
study team at study entry, 2 weeks, 1, 2, 3 and 8 months.
Lumbar puncture
All patients underwent lumbar puncture either at the re-
ferring centre or on admission to PNT hospital. Lumbar
puncture was repeated at days 30 and 90 following study
entry/treatment initiation. Cerebrospinal fluid (CSF) in-
vestigations included cell count, glucose, protein, lactate,
Gram’s stain, and India ink test, and culture for fungi and
pyogenic bacteria. CSF Ziehl-Neelsen smear and culture
were not available at referring centres. When patients
were referred from other centres, lumbar puncture was
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only repeated at baseline if felt to be clinically indicated by
the attending physician. The GeneXpert test was not avail-
able at the time the study took place.
Other investigations
All children had haematology and biochemistry investi-
gations according to standard of care in the hospital.
Sputum was examined for acid fast bacteria (AFB) when
available; gastric washings for AFB were done at the dis-
cretion of the attending physician. All patients had HIV
testing - counselling and HIV testing were available for
the parents of children diagnosed with HIV. All patients
had a chest radiograph performed at study entry. 40 pa-
tients were entered into a descriptive radiological sub-
study and underwent cranial Magnetic Resonance
Imaging (MRI) at study entry, on day 60 and day 270.
Other imaging was performed at the discretion of the at-
tending physician.
Classification of severity
All patients were graded for severity at study entry. For
children older than 5 years severity was graded accord-
ing to a modified United Kingdom Medical Research
Council criteria based on Glasgow Coma Score: Grade I
had a Glasgow coma score (GCS) of 15/15 with no focal
neurological signs, grade II either had a GCS 11–14 or
GCS 15 with focal neurological signs, Grade III had a
GCS of ≤ 10.
For children less than 5 years of age severity of TBM
was graded according to the Blantyre Coma Score. Pa-
tients with grade I disease had a Blantyre coma score of
4–5 with no focal neurological signs; patients with grade
II disease had a Blantyre coma score of 2–3 or a score of
4–5 with focal neurological signs; and grade III had a
Blantyre coma score ≤1.
Treatment and follow-up
Anti-tuberculosis treatment was according to Vietnam-
ese treatment guidelines, which at the time were consist-
ent with the 2006 WHO guidelines. Patients received
oral isoniazid (5 mg/kg), rifampicin (10 mg/kg), pyrazi-
namide (25 mg/kg), ethambutol 15 mg/kg and intramus-
cular streptomycin (15 mg/kg) for 2 months, followed by
oral isoniazid, rifampicin, pyrazinamide and ethambutol
for 1 month and oral isoniazid, rifampicin, and etham-
butol at the same doses for 5 months [2HRZES/1HRZE/
5HRE]. Streptomycin was not used for HIV-infected pa-
tients. Patients with MRC grades II and III and BCS
grades II and III disease received adjuvant dexametha-
sone for the first six weeks; patients with MRC grade I
and BCS grade I received adjuvant dexamethasone for
4 weeks as per Vietnamese guidelines [11]. All patients
were reviewed daily by the study team while in-patients,
at days 30, 60 and 90, and on completion of treatment
after 8 months. DOT was used to secure and monitor
treatment adherence, and drugs were administered via
nasogastric tube to unconscious children.
Assessment of outcome
We were interested in two outcomes: survival, and a
combined endpoint of neurological disability or death.
Disability status was assessed at the end of 8 months of
treatment with the use of the two simple questions
(“Does the child require help from anybody for everyday
activities [e.g., eating, drinking, washing, brushing teeth,
and going to the toilet]?” and “Has the illness left the
child with any other problems?”) and the modified Ran-
kin scale (scores range from 0 [no symptoms at all] to 6
[death]) and was classified as good (i.e., no disability),
intermediate, severe, or death, as described elsewhere
[11]. For children under 5 years, the response was deter-
mined by the study clinician in relation to the expected
functioning in normal children of the same age.
Study size
The study was designed as a prospective descriptive
study to include all patients less than or equal to 15 years
of age presenting with suspected TBM to Pham Ngoc
Thach Hospital. Approximately 100 such patients are
admitted each year, and we planned to recruit 100 con-
secutively admitted patients.
Statistical analysis
The raw data was imported into a secure anonymised
in-house data management system (CliRes). Between
group comparisons of baseline characteristics were
based on the Wilcoxon rank sum test and Fisher’s exact
test for continuous and categorical variables, respect-
ively. Mortality at 8 months was estimated with the
Kaplan-Meier method. Univariate Cox regression was
used to identify significant factors influencing time to
death. Factors relating to the probability of a combined
endpoint of neurological sequelae (intermediate or se-
vere disability) or death were determined using univari-
ate logistic regression and the Firth correction was
applied in case of separation [18]. Multivariable regres-
sion models were not fitted due to the relatively low
number of events and large number of factors of inter-
est. All analyses were performed using R software ver-
sion 2.9.1 [19].
Results
Demographic and clinical characteristics
Enrollment was conducted between October 2009 and
March 2011. During this period 133 children were ad-
mitted to PNT hospital with suspected TBM. Twelve
children declined to join the study and 21 were not re-
cruited because they were already receiving treatment.
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Follow-up completed in December 2011. The median
duration from first hospital admission to making the
diagnosis of TBM (and instigation of treatment) was
11 days (range 1–74 days).
Baseline characteristics and outcomes for the cohort
are shown in Table 1.
Fifty-six percent (n = 56/100) of patients were male.
The majority of children (67 %) were less than 5 years
old (median age 32.5 months, range 2 to 180 months).
Four of 96 children tested were HIV infected (4 %); 5 %
(n = 5/96) were hepatitis B surface antigen positive. Con-
comitant extra-pulmonary TB was common, seen in 42
patients (36 pulmonary, 4 pulmonary with peripheral
lymphadenitis, 1 pulmonary disease with pleural involve-
ment, and 1 pulmonary disease with concomitant TB
arthritis. A family history of TB was reported for 27 pa-
tients (27 %); one patient had a previous history of TB.
Fever, vomiting and nuchal rigidity were the most fre-
quently elicited symptoms. Seizures were common re-
ported in 39 cases. Headaches occurred in at least 49
(49 %) cases - in 44 cases (44 %) the presence of head-
ache was uncertain because the child was too young to
describe the symptom. Of 33 (33 %) children ≥ 5 years of
age, 16 (48 %) had MRC grade I disease, 11 (33 %) grade
II disease, and 6 (18 %) grade III disease. The remaining
67 children under 5 years were graded using the Blan-
tyre coma score (BCS): BCS I (4–5): 43 (64 %), BCS II
(2–3): 12 (18 %) and BCS III (0–1): 12 (18 %) (Table 1).
Focal neurological signs were frequent occurring in
58 %, most commonly VIth cranial nerve palsies (22 %),
followed by hemiplegia (20 %), VIIth cranial nerve palsy
7 %, paraplegia 6 %, monoparesis 4 %, IIIrd cranial nerve
palsy 4 %, optic nerve atrophy 3 %, and quadriparesis
2 %. Four patients (4 %) were lost to follow up after
3 months of treatment.
Cerebrospinal fluid results
Lumbar puncture was performed on all patients (n =
100) at referring hospitals; 22 (22 %) children had repeat
lumbar puncture at PNT. All CSF was analyzed for pro-
tein, lactate and glucose concentrations, and for cell
count and differentials (Table 2). The median white cell
count was 202 cells/uL. 92 of 95 (97 %) patients had
lymphocyte predominance (>50 %). The mean CSF:blood
glucose ratio was 0.25 (range 0.07 to 0.69; 7 of 100 pa-
tients had ratios >0.5). 77 patients had CSF lactate mea-
sured; the median was 5.3 mmol/L (10th and 90th
centiles 2.36 and 8.8 mmol/L respectively). All but 8 pa-
tients had elevated CSF protein concentrations (median
1.2 g/L, upper limit of the normal range 0.4 g/L).
Microbiology results
None of 22 CSF samples taken at PNT were AFB smear
positive, However, M. tuberculosis was cultured from 6
of these samples. Smears of sputum and gastric aspirates
were positive for AFB in only 2 (7 %) of 29 patients and
5 (7 %) of 67 patients, respectively. Drug susceptibility
testing was not performed.
TBM classification
Six cases met the definition of definite TBM. Sixty-six
cases fulfilled the case definition of probable TBM: seven
had positive AFB smears and/or M. tuberculosis cultured
from sputum or gastric aspirate; 33 had abnormal chest
X-rays consistent with TB and an abnormal brain im-
aging, and 26 cases had an abnormal CT or MRI brain
imaging consistent with TBM.




Number affected (%) Median duration in
days (range)
Fever 96/97 (99 %) 23; (6–96)
Vomiting 76/100 (76 %) 13; (1–96)
Weight loss 59/98 (60 %) 15.5; (7–90)
Confusion 15/100 (15 %) 10.4; (2–30)
Unconsciousness 27/100 (27 %) 5.3; (1–16)
Headachea 49/55 (89 %) 21; (4–66)
Fits 39/100 (39 %) 8.5; (1–35)







Monoplegia 4/98 (4 %)




III nerve palsy 4/98 (4 %)
VI nerve palsy 20/98 (20 %)
VII nerve palsy 7/98 (7 %)
Anemia
(Hb < 11 g/dL)
46/99 (46 %)
HIV infection 4/96 (4 %)
HBV infection 5/96 (5 %)
MRC Grades
>5 years (33)
I: 16 (48 %) II: 11 (33 %) III: 6 (18 %)
Blantyre <
5 years (67)
4–5: 43 (64 %) 2–3: 12 (18 %) 0–1: 12 (18 %)
Deaths 15/100 (15 %)
Sequelae
Severe 6/81 (7 %)
Intermediate 21/81 (26 %)
aUnable to ascertain in 44 due to the age of the child; headache was not
assessed for one additional subject
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The remaining 28 cases fulfilled the definition of pos-
sible TBM, with clinical features and CSF biochemistry
consistent with the diagnosis. The differences in baseline
characteristics and outcome between definite/probable
and possible cases are illustrated in Table 2. There were
statistically significant lower rates of altered sensorium,
neck stiffness and motor deficits at baseline, and a re-
duced risk of neurological sequelae in possible cases,
suggesting that these patients may have had less severe
disease.
Imaging findings
All children had chest X-ray examinations at admission:
42 % (42/100) had abnormalities consistent with TB
(14 % mediastinal lymphadenopathy 14 %, consolidation
11 %, miliary pattern 9 %, nodules 6 %, cavity 1 % and
atelectasis 1 %).
Forty-three patients underwent cranial MRI before be-
ginning treatment (42 with contrast enhancement).
Findings are shown in Table 3.
Abnormalities were frequent, detected in 86 % of pa-
tients: 62 % (26/42) had basal meningeal enhancement,
44 % (19/43) hydrocephalus, 30 % (13/43) infarctions
and 14 % (6/42) tuberculomas. 35 of these 43 patients
had repeat cranial MRI scans performed 60 days post
randomization: 37 % (13/35) had basal meningeal en-
hancement, 29 % (10/35) hydrocephalus, 34 % (12/35)
infarctions and 29 % (10/35) tuberculomas.
Death and sequelae
Fifteen patients died by 8 months (Kaplan-Meier estimate
of mortality 15.7 %, 95CI: 9.56–24.3 %, 4 patients lost to
follow-up). Eight (53 %) deaths occurred within the first
6 days of treatment; 14 within 45 days of diagnosis. At the
end of treatment, six of 81 surviving patients (7.4 %) were
classified with severe disability and 21/81 (26 %) were
classified with intermediate disability (Table 1).
Baseline predictors associated with increased risk of
death or neurological sequelae are shown in Table 4.
More severe BCS was predictive of increased risk of
death, as were history of coma, fits, focal neurological defi-
cits and CSF levels of protein, lactate and glucose. The
study did not detect a statistically significant association
between risk of death and MRC score but this may be due
to the low number of children in the study aged ≥5 years.
However, there was a consistent increase in the hazard of
death as MRC grade worsened. Hydrocephalus, neck stiff-
ness and MRC grade at baseline were associated with an
increased risk of the combined endpoint of neurological
sequelae or death (p = 0.01). Neither brain infarctions nor
Table 2 Baseline characteristics of possible TBM and definite/probable TBM
Variables Possible TBM (n = 28) Definite/Probable TBM (n = 72) P-value for comparison
Agea (months) 24.5 (2–165) 36.5 (2–180) 0.09
Male (%) 18/28 (64 %) 38/72 (53 %) 0.03
Fever 28/28 (100 %) 71/72 (99 %) 0.99
Symptom durationa (days) 16 (6–60) 19.5 (6–96) 0.172
Vomiting 20/28 (71 %) 56/72 (78 %) 0.50
Altered sensorium 6/28 (21 %) 36/72 (50 %) 0.01
Fits 9/28 (32 %) 30/72 (40 %) 0.38
Neck stiffness 17/28 (61 %) 58/72 (81 %) 0.04
Motor deficit 4/25 (16 %) 28/60 (47 %) 0.01
Cranial nerve palsy 9/28 (32 %) 18/72 (25 %) 0.91
HIV infection 1/28 (4 %) 3/72 (4 %) 0.99
HBV infection 2/28 (7 %) 3/72 (4 %) 0.86
Family TB history 7/28 (25 %) 19/72 (26 %) 0.89
Death 2/27 b (7 %) 13/69 (19 %) c 0.28
Permanent sequelae 2/25 (8 %) 25/56 (45 %) 0.002
CSF WCCa (cells/uL) 144 (4–780) 150 (1–802) 0.37
CSF Lympha (cells/uL) 80 (40–100) 80 % (50–100) 0.44
CSF Proteina (g/L) 0.8 (0.2–5) 1.3 (0.1–4.8) 0.08
CSF Lactatea (mmol/L) 4.3 (1.4–8.8) 5.6 (1.21–19.2) 0.08
CSF: Blood Glucose ratioa 0.30 (0.09–0.61) 0.25 (0.07–0.69) 0.51
a Values are medians/ranges
b1 lost to follow-up
c3 lost to follow-up
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basal meningeal enhancement identified on brain imaging
were associated with mortality or the combined endpoint.
Two patients developed drug induced liver injury
(DILI) according to the classification of antituberculosis
drug-induced hepatotoxicity based on the WHO Ad-
verse Drug Reaction Terminology [20]. This occurred at
2 and 4 weeks following treatment initiation. Neither
case was infected with Hepatitis B or C virus. In both
cases, PZA was discontinued completely and INH and
RIF were reintroduced successfully. Both patients
survived.
Uniform case definition for tuberculous meningitis
After this study was designed and recruited, a consensus
document was published suggesting criteria to standardize
the categorization of TB meningitis as possible, probable
or definite, in order to allow comparison of different pop-
ulations in intervention trials [21]. The criteria are based
upon the expert opinion of a number of international ex-
perts. We reclassified our patients according to these new
criteria, and this resulted in 18 cases moving from the
‘probable’ diagnosis to the new ‘possible’ category, and 8
cases moving from our ‘possible’ category to the new
‘probable’ category. Following re-categoristaion, male sex
was no longer statistically significantly differently distrib-
uted between possible and probable/definite cases; altered
sensorium, neck stiffness, motor deficit and permanent se-
quelae remained significantly more common amongst
probable and definite cases. Cranial nerve palsies and
death became significantly more associated with probable
and definite cases.
Discussion
This study demonstrates the challenges in delivering ef-
fective treatment for TBM in children in Vietnam. First,
TBM is associated with considerable mortality and mor-
bidity, with a risk of death at the end of treatment of
15 %, and 33 % of survivors having intermediate or se-
vere disability. These figures are similar to those re-
ported from other studies in children, and to the rates of
death and disability seen in HIV uninfected adults with
TBM in Vietnam, but while in adult disease considerable
progress has been made and large studies are on-going,
childhood TBM remains a neglected area [11, 13, 22–
29]. Treatment guidelines for children are largely derived
from studies in adults, and although efforts are under-
way to develop pediatric formulations in appropriate ra-
tios, at the present time dosing schedules are limited by
adult fixed dose combination tablets. Randomised con-
trolled trials and pharmacokinetic studies of novel dos-
ing strategies and agents in children are needed to
ensure treatment is optimized.
Secondly, the timely instigation of treatment in TBM
remains a significant challenge, even in countries such
as Vietnam where the burden of TB is high and the diag-
nosis is at the forefront of clinicians’ minds. In this
study, the median time from presentation to treatment
was 19 days, and 50 % of deaths occurred within the first
6 days of treatment. Earlier instigation of treatment may
be able to prevent these deaths. Delays in diagnosis and
treatment are likely explained by 3 main factors. First,
poverty is a barrier to accessing health care. Since the
study Vietnam has made important progress in rolling
out free access to healthcare for children under the age
of 6 years; however, this is beyond the means of many
countries where the TB burden is highest. Secondly,
TBM presents in a non-specific manner and it is rare to
confirm the diagnosis microbiologically even in high re-
source settings. In this study, a definitive diagnosis was
made in only 6 % of cases. This is partly explained be-
cause only 22 % (22/100) of patients had a CSF smear
and culture, although the study is representative of real
world practice. Of note, no patients were CSF smear
positive. Most papers report finding AFB in fewer than
20 % of TBM patients [30]. Improving laboratory train-
ing and infrastructure, and improving access to WHO
endorsed technologies such as the GeneXpert, would
potentially reduce this delay but will not alter the fact
that clinical specimens from children are limited both by
their volume and their paucibacillary nature [31]. An ad-
equate volume of CSF significantly affects the likelihood
of confirming the diagnosis [32] and appropriate sam-
pling for TB at other sites should be performed. More-
over, while TB diagnostic tests remain poorly sensitive,
increasing the capacity to identify and exclude other
central nervous system pathogens is key in giving clini-
cians the confidence to instigate treatment in a timely
manner and will reduce unnecessary prescription of
lengthy TB regimens. Of note, an approach that has
shown promise in South African children with TBM,
which resulted in a doubling of diagnostic sensitivity, is
Table 3 Baseline brain MRI scan results for 43 patients
Finding Absolute frequency (%)
Any abnormality 37/43 (86 %)
Meningeal enhancement 26/42 (62 %)
Basal 25 (60 %)
Sylvian Fissure 16 (37 %)
Suprasellar cistern 4 (9 %)
Hydrocephalus 19/43 (44 %)
Tuberculoma 6/42 (14 %)
Infarction 13/43 (30 %)
Basal Ganglia 8/43 (19 %)
Cerebral cortex 3/43 (7 %)
Internal capsule 1/43 (2 %)
Brain stem 1/43 (2 %)
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Table 4 Univariate analysis of potential predictors of mortality and neurological sequelae in patients with tuberculous meningitis
Characteristic Time to death (N = 100) Neurological sequelae or death (N = 96)
Death/No at risk HR (95 % CI) P Events/No at risk OR (95 % CI) P
Sex
aMale 10/56 (17.9 %) 0.61 0.36 23/54 (42.6 %) 1.11 0.80
Female 5/44 (11.4 %) (0.21–1.78) 19/42 (45.2 %) (0.49–2.52)
Age
a<5 years 11/67 (16.5 %) 0.70 0.54 30/64 (46.9 %) 0.68 0.38
≥ 5 years 4/33 (12.1 %) (0.22–2.20) 12/32 (37.5 %) (0.28–1.61)
Duration of symptoms N = 89 1.00 0.4 – 1.01 0.43
(per +1 day) (0.98–1.01) (0.98–1.04)
Neck stiffness
aNo 1/25 (4.0 %) 5.15 0.11 5/24 (20.8 %) 4.02 0.01
Yes 14/75 (18.7 %) (0.68–39.16) 37/72 (51.4 %) (1.44–13.18)
HIV co-infection
aNo 13/92 (14.1 %) 1.85 0.55 39/88 (44.3 %) 0.42 0.43
Yes 1/4 (25.0 %) (0.24–14.17) 1/4 (25.0 %) (0.02–3.42)
BCS Grade
age <5 years
aBI 0/43 (0 %) 1.00 <0.001 10/40 (25.0 %) 1.00 <0.001
BII 3/12 (25.0 %) 27.96 b 9/12 (75.0 %) 9.00
(2.71–3760) (2.21–47.06)
BIII 8/12 (67.0 %) 94.64 b 11/12 (91.7 %) 33.00
(11.71–12,260) (5.44–643.12)
TBM grade
(age ≥ 5 years)
aI 1/16 (6.3 %) 1.00 0.28 2/15 (13.3 %) 1.00 0.01
II 1/11 (9.1 %) 1.41 5/11 (45.5 %) 5.41
(0.09–22.5) (0.81–36)
III 2/6 (33.3 %) 6.26 5/6 (83.3 %) 32.5
(0.57–69.2) (2.4–443)
Convulsions
aNo 5/61 (8.2 %) 3.46 0.02 20/59 (33.9 %) 2.86 0.01
Yes 10/39 (25.6 %) (1.18–10.13) 22/37 (59.5 %) (1.24–6.81)
Decreased level of consciousness
aNo 1/58 (1.7 %) 22.9 <0.001 10/54 (18.5 %) 14.08 <0.001
Yes 14/42 (33.3 %) (3.01–174.3) 32/42 (76.2 %) (5.46–39.85)
Focal neurological deficits
aNo 0/53 (0 %) 15.66 0.01 6/50 (12.0 %) 15.4 <0.001
Yes 4/32 (12.5 %) (1.67–2075) 21/31 (67.7 %) (5.22–51.96)
Extra meningeal TB
aNo 6/51 (11.8 %) 2.3 0.11 19/57 (33.3 %) 2.87 0.01
Yes 9/30 (30.0 %) (0.82–6.45) 23/39 (59.0 %) (1.25–6.80)
TB culture
aNegative 2/14 (14.3 %) 2.72 0.33 4/16 (25.0 %) 4.50 0.16
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the use of more than one nucleic acid amplification test
on CSF [33]. However, the investigators still found a
combination of microscopy and culture to be most ef-
fective. We have found GeneXPert and CSF smear to
have similar sensitivities of in adult patients; the chal-
lenge for Vietnam remains in obtaining significant vol-
umes of CSF from infants and balancing the risk of
investigation with the benefits of a definitive diagnosis
[31]. The early identification of drug resistance is likely
to be an important factor in improving outcomes. A
South African study found that drug resistance was asso-
ciated with delays in instigation of effective treatment,
and that multidrug resistance was associated with worse
outcomes [34]. In this study isoniazid mono-resistance
was not clearly associated with worse outcomes [34].
However, this mimics the experience in adult patients –
initial small studies failed to show a deleterious effect of
isoniazid mono-resistance on outcome, but later larger
datasets demonstrated that indeed such resistance is dis-
advantageous [35, 36].
Thirdly, TB treatment is onerous, both in regards to
side effects and duration, which may lead to reluctance
to start empirical treatment where the risk and conse-
quences of disease are perceived to be low. However, M.
tuberculosis has been reported to be a more frequent
cause of meningitis than pyogenic organisms in South
Africa – given that 50 % of deaths are occurring within
the first week of treatment a case could be made for
early empirical TB treatment in such centres [37]. Few
data exist on the optimal duration of treatment for
TBM. Drugs such as the fluoroquinolones, which have
good tolerability and excellent CSF penetration, poten-
tially offer more effective and palatable treatment
regimens, but are relatively untested in children [38].
Randomized controlled trials in children specifically de-
signed to improve TB treatment by 1) identifying shorter
equally effective courses and 2) new treatment combina-
tions, may go some way to addressing this issue, al-
though recent trials in adult patients have had mixed
results [39–42]. The effective dose of rifampicin appears
to be key in improving outcomes. Such regimes would
enable a move towards an empirical therapeutic ap-
proach similar to that used in acute bacterial meningitis
to be employed in high burden settings.
Finally, it is reassuring that drug induced liver injury
necessitating treatment interruption was rare and not as-
sociated with a poor outcome in this study, affecting just
2 % of the patients. Our study is small and thus our esti-
mates are somewhat imprecise. However, the rate is con-
siderably lower than the 13 % quoted for DILI in adults,
supporting the concept that higher doses could be used
in children, as advocated in the recent WHO guidelines.
[2, 43–45].
Our study had some limitations. It was limited by its
small size, and thus estimates around the rates of death
and other sequelae lack precision, although findings are
generally in keeping with other series [13]. Secondly, we
used all-cause mortality. However, 50 % of all deaths oc-
curred within 1 week of treatment initiation, and the
rates of co-morbidities (such as HIV) were low, meaning
that it is reasonable to assume that all deaths were either
a direct consequence of TB or a result of its sequelae.
Thirdly, children were only followed up until the end of
treatment, and we may have missed later deaths and re-
lapse. The main limitation is the low rate of microbio-
logical confirmation of tuberculosis. This is consistent
Table 4 Univariate analysis of potential predictors of mortality and neurological sequelae in patients with tuberculous meningitis
(Continued)
Positive 2/3 (66.7 %) (0.38–19.4) 3/5 (60.0 %) (0.56–45.4)
Hydrocephalusc
aNo 2/31 (6.5 %) 3.46 0.10 6/31 (19.4 %) 9.72 <0.001
Yes 6/30 (20.0 %) (0.70–17.16) 21/30 (70.0 %) (2.97–32)
Cranial nerve palsy
No 14/70 (20.0 %) 5.42 0.10 29/70 (41.4 %) 0.71 0.45
Yes 1/26 (3.8 %) (0.71–42.2) 13/26 (50.0 %) (0.29–1.75)
CSF Protein N = 99 1.74 0.002 N = 94 1.65 0.01
(per + 1 g/L) (1.22–2.49) (1.14–2.51)
CSF Lactate N = 77 1.14 0.04 N = 73 1.20 0.03
(per + 1 mmol/L) (1.01–1.29) (1.01–1.47)
CSF Glucose N = 100 0.45 0.05 N = 96 0.65 0.10
(per + 1 mmol/L) (0.20–0.98) (0.38–1.08)
aBaseline category. HR and OR give comparisons to the baseline category. P-value is an overall likelihood ratio test for the significance of the factor
bModel fitted by logistic regression with Firth correction
chydrocephalus diagnosed by MRI brain (43 patients or CT brain 19 patients)
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with other studies in children and represents the very
real practical difficulties of managing these children. It is
possible that some of these cases, particularly those
meeting the ‘possible’ case definition, may have had
some other pathology. However, when the possible cases
are excluded, then the mortality and morbidity rate rises
further underlying the need to improve diagnostics and
treatment for this devastating disease.
Our study was designed and completed before the publi-
cation of the universal case definition (UCD) for TBM was
published and thus we present our results as originally
intended, with a secondary analysis using this classification
[21]. The UCD is based upon a non-linear scoring system
derived from expert opinion, and has been shown to mis-
classify 14 % of cases of culture proven TBM as possible
TBM in children in a South African study [46]. This under-
lines the danger of using this research tool as a diagnostic
aid, particularly where microbiological diagnostic facilities
are poorly developed. Moreover, it is not yet clear that the
UCD achieves that which it set out to achieve – i.e allowing
robust comparison of patients across diverse study groups
according to the UCD defined likelihood of there being def-
inite, probable or possible TBM. As an illustration, a study
from South Africa found that patients with ‘possible’ versus
other ‘probable/definite’ TBM had significant differences in
CSF protein concentrations and CSF/serum glucose con-
centrations. This difference was not apparent in our chil-
dren, suggesting that our ‘possible’ cases may be more likely
to actually have TBM than possible cases from South
African series [47]. There is a need to develop more robust
data-driven classification systems, and given the number of
patients enrolled into intervention trials in the last 15 years
this should be feasible [11, 15, 38, 48].
Conclusions
Tuberculous meningitis in children carries significant
morbidity and mortality in Vietnam. A particular
challenge is in reducing the time to diagnosis, and in-
stitution of effective treatment. However, improving
outcomes will also require the development of treat-
ment regimens tailored to children. Given the recent
disappointing results of fluoroquinolone boosted treat-
ment regimens in adults with TBM, randomized con-
trolled trials of boosted rifampicin dosing would seem
the most important strategy to develop.
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